

2022 Medicare Opioid Guidance

OptumRx Medicare Part D MAPD, PDP, EGWP, MMP and PACE Plans

Effective Date: January 1, 2022

Effective January 1, 2019, OptumRx® Medicare Part D plans will implement opioid prescription requirements based on the Centers for Medicare & Medicaid Services (CMS) guidance, United States Drug Enforcement Administration (DEA) requirements, United States Center for Disease Control (CDC) guidance, as well as OptumRx strategies. These new policies include improved safety edits when opioid prescriptions are dispensed at the pharmacy and drug management programs for patients determined to be at-risk for misuse or abuse of opioids or other frequently abused drugs. We are making these changes to promote safe and appropriate use of opioids and to limit excess supply in the market. This notice describes the opioid edits, reject codes, messaging and recommended action for pharmacies.

To communicate CMS opioid limitations within a claim billing transaction, OptumRx® will apply guidance from the National Council for Prescription Drug Programs (NCPDP). This recommendation structures how opioid utilization edits are defined in claim rejections and overrides. It can be applied across similar opioid patient safety programs.

OptumRx urges pharmacists, when appropriate, to resolve opioid safety limits/edits at the point-of-service. Please use this Guide or refer to the OptumRx Provider Manual to help with resolving rejected prescription claims associated with new opioid safety edits and/or supply limits.

Note: One claim may hit multiple opioid safety edits.

To view payer sheets, visit: https://professionals.optumrx.com/resources/payer-sheets.html. To reduce processing errors, please confirm the information on member's ID card prior to submitting prescription claims.

Should you have any questions or require assistance, please contact the OptumRx Pharmacy Help Desk at **(800) 797-9791** (24 hours a day, 7 days a week).

Please distribute immediately.

Opioid Edit	Description	Standard Reject Code	Standard	Reco	ommended Action / Additional	Detail
Name 7-day supply	Medicare Part D patients	/ Description 88 – DUR Reject Error	Messaging 7-DAY MAX	Additional Detail		
limit for opioid	who have not filled an		FOR OPIOID		e 7-day supply restriction if they a	are in Long-Term Care (LTC)
naïve patients	opioid prescription	925 – Initial Fill's Day	NAIVE		e care, are treating cancer relate	
(Hard reject)	recently will be limited to	Supply Exceeds Limits		sickle cell anemia.		•
	a supply of 7 days or		If exempt, use			
	less.	569 – Provide Notice:	DUR/PPS	Recommended Action		
		Medicare Prescription	code		d the member should be exempt,	
	Subsequent prescriptions filled during	Drug Coverage and Your Rights	RxHelp	LTC, Hospice, or Palliative Ca	are, resubmit the claim using the	following DUR/PPS codes:
	the plan's review window	Tour Rights	8007979791	Reason for Service Code	Professional Service Code	Result of Service Code
	(generally 90-120 days)		0007070701	MX Excessive Duration	M0 Prescriber Consulted	4B Filled, Palliative Care
	will not be subject to the			Alert	We i receiber consumed	4C Filled, Hospice
	7 day supply limit.				R0 Pharmacist Consulted Oth	
	, ,,,				The Friantiacion Contractor Curr	4C Filled, Hospice
	This edit should not impact patients who already take opioids.			opioid claim within the last 120	mRx and the pharmacy has record days, resubmit the claim using	
				codes:		
				Reason for Service Code	Professional Service Code	Result of Service Code
				MX Excessive Duration	M0 Prescriber Consulted	4J Filled, Pt Not Opioid
				Alert	MR Medication Review	Naïve
					R0 Pharmacist Consulted Oth	r
					d the member should be exempt vain or sickle cell anemia, resubm	
				Reason for Service Code	Professional Service Code	Result of Service Code
				MX Excessive Duration Alert	M0 Prescriber Consulted	4D Filled, Cancer Treatment
					MR Medication Review	4D Filled, Cancer Treatment
					R0 Pharmacist Consulted	4D Filled, Cancer
					Othr	Treatment
				when the full days supply is n pharmacy notice <u>Medicare Pr</u> advise the member, the memb	Ived, and the prescription canno ot dispensed, distribute a copy o escription Drug Coverage and Your's appointed representative, or ghtheir prescription drug plan.	f the standardized CMS our Rights to the patient, and

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging		Recommended Action / Add	ditional Detail
Opioid Care Coordination edit at 90 morphine milligram equivalent (MME) (Soft Reject)	This edit will trigger when a patient's cumulative MME per day across his/her opioid prescription(s) reaches or exceeds 90 MME when prescribed by two or more prescribers. If the pharmacist recently consulted with the prescriber and has up-to-date clinical information	88 – DUR Reject Error 922 – Morphine Equivalent Dose Exceeds Limits 569 – Provide Notice: Medicare Prescription Drug Coverage and Your Rights	OCC. To Override, use DUR/PPS code If > 50 MME, co- prescribe Naloxone for safety RxHelp 8007979791	calculate the daily M reject a refill. Members are exempreceiving palliative anemia. If the pharmacy has	MME, excluding claims that have lend that have lend the from this restriction if they are in care, are treating cancer-related purposes of the member should be ative Care or being treated for can	entify overlapping opioid claims to ess than a 25% overlap in order to not Long-Term Care (LTC) or Hospice, ain, or are diagnosed with sickle cell exempt, due to the member being in cer related pain, resubmit the claim
	(e.g., Prescription Drug Monitoring Program (PDMP) system or other records), additional			Reason for Service Code HD High Dose	Professional Service Code M0 Prescriber Consulted	AB Filled, Palliative Care
	consultation with the prescriber is not expected.					4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice
					MR Medication Review	4D Filled, Cancer Treatment
					R0 Pharmacist Consulted Othr	4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice
				with current pharma appropriateness. Th	cy practice to verify the prescription	The consultation should be consistent on and to validate its clinical ts to inform the prescriber of other
				may include the date	e, time, name of prescriber, and burnintent, provided information on	override code. The documentation rief note that the prescriber confirmed patient exclusion, or could not be
					nfirms that greater than 90 MME is ving DUR/PPS Codes:	medically necessary, then resubmit
				Reason for Serv Code	Code	Result of Service Code
				HD High Dose Ale	rt M0 Prescriber Consulted	1G Filled, Prescriber Approvl
				a copy of the standa	ardized CMS pharmacy notice Med	on cannot be filled as written, distribute dicare Prescription Drug Coverage and e member's appointed representative,

		or the prescriber to request a coverage determination through their prescription drug plan.
		IMPORTANT : For Opioid Care Coordination Safety Edit (OCC)*, Pharmacies should only use the override code M0-1G upon completion and documentation of the care coordination activities with prescribers. Plan sponsor may consider auditing pharmacy's documentation.

Opioid Edit	Description	Standard Reject	Standard		Recommended Action / Add	ditional Detail	
Name		Code / Description	Messaging				
Cumulative	Some plans may	88 – DUR Reject Error	OPIOID MME				
MME Opioid	implement a hard edit		PA REQ'D	While not all Optum	nRx clients have implemented the h	nard rejection, the majority of our	
Safety Edit -	when a	922 – Morphine		clients have.			
200 MME or more	patient's cumulative opioid daily dosage reaches 200 MME or	Equivalent Dose Exceeds Limits	If exempt, use DUR PPS code	OptumRx will look back 120 days in claim history to identify overlapping opioid claims to calculate the daily MME, excluding claims that have less than a 25% overlap in order to not			
(Hard Reject)	more.	569 – Provide Notice:	If >50 MME, co-	reject a refill.			
		Medicare Prescription	prescribe				
		Drug Coverage and	Naloxone for Proceedings 1985	Members are exem	pt from this restriction if they are in	Long-Term Care (LTC) or Hospice,	
		Your Rights	safety	receiving palliative anemia.	care, are treating cancer-related p	ain, or are diagnosed with sickle cell	
		G4 – Prescriber must	RxHelp				
		contact plan	8007979791	If the pharmacy has	s confirmed the member should be	exempt, due to the member being in	
				LTC, Hospice, Pall	iative Care or being treated for can-	cer-related pain, resubmit the claim	
				with the following D	OUR/PPS Codes:		
				Reason for	Professional Service Code	Result of Service Code	
				Service Code			
				HD High Dose	M0 Prescriber Consulted	4B Filled, Palliative Care	
						4C Filled, Hospice	
						4D Filled, Cancer Treatment	
						4K Pscbr Expt - Cancer/PalCare	
						4L Pscbr Expt – Hospice	
					MR Medication Review	4D Filled, Cancer Treatment	
					R0 Pharmacist Consulted Othr	4B Filled, Palliative Care	
						4C Filled, Hospice	
						4D Filled, Cancer Treatment	
						4K Pscbr Expt – Cancer/PalCare	
						4L Pscbr Expt – Hospice	
				a copy of the stand	lardized CMS pharmacy notice Med	on cannot be filled as written, distribute dicare Prescription Drug Coverage and e member's appointed representative,	
						through their prescription drug plan.	

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging		Re	ecommended Action / Add	litional Detail
Long-Acting Opioid Duplicate Therapy (Soft Reject)	CMS requires a soft reject for duplicate therapy with long-acting opioid drugs.	88 – DUR Reject Error 569 – Provide Notice: Medicare Prescription Drug Coverage and Your Rights	LA Opioid Dup Ther. Use DUR/PPS Code RxHelp 800797979	acting opioid claims of the same drug, ar change in therapy. Members are exempreceiving palliative anemia. Recommended Act If the pharmacy has	on the confirmation of the confirmation of the confirmative C	apping claims will be excluded and that have less than a this restriction if they are in the treating cancer-related particle of the member should be are or being treated for cancer.	ntify two or more overlapping long- led if they are for a different streng th 25% overlap in order to not reject Long-Term Care (LTC) or Hospice, ain, or are diagnosed with sickle cell exempt, due to the member being in cer-related pain, resubmit the claim
				Reason for Service Code TD Therapeutic Duplication	MO P	rescriber Consulted Medication Review harmacist Consulted Othr	Result of Service Code 4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice 4D Filled, Cancer Treatment 4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice
				member is changing	g thera y, then	pies, or that the combination	and if the prescriber confirms that n of the long- acting opioid drugs is following DUR/PPS Codes: Result of Service Code 1G Filled, Prescriber Approvl
				If the rejection cann a copy of the standa	ardized atient,	esolved, and the prescriptio I CMS pharmacy notice <u>Mec</u> and advise the member, the	n cannot be filled as written, distribute licare Prescription Drug Coverage and e member's appointed representative, through their prescription drug plan.

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging		Re	ecommended Action / Add	litional Detail
Opioid – Medication Assisted Treatment (MAT) / Opioid Use Disorder (OUD) Combin ation (Soft Reject)	CMS requires a soft reject for an opioid claim dispensed after a member has filled a Medication Assisted Treatment (MAT) / Opioid Use Disorder (OUD) claim.	88 – DUR Reject Error 569 – Provide Notice: Medicare Prescription Drug Coverage and Your Rights	Buprenorphine Hx Call MD Use DUR/PPS Codes RxHelp 8007979791	history is overlapping Members are exempled receiving palliative anemia. Recommended Actifithe pharmacy has	ng the s pt from care, ar tion s confir ative C	submitted opioid claim, trigg this restriction if they are in re treating cancer-related pa med the member should be are or being treated for can	couprenorphine claim in the member's ering the soft reject. Long-Term Care (LTC) or Hospice, ain, or are diagnosed with sickle cell exempt, due to the member being in cer-related pain, resubmit the claim
				Reason for Service Code DD Drug-Drug		rescriber Consulted	Result of Service Code 4B Filled, Palliative Care
				Interaction			4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice
						Medication Review harmacist Consulted Othr	4D Filled, Cancer Treatment 4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice
							if the prescriber confirms that the claim with the following DUR/PPS
				Reason for Ser Code	vice	Professional Service Code	Result of Service Code
				DD Drug-Drug Interaction	_	M0 Prescriber Consulted	1G Filled, Prescriber Approvl
				a copy of the stand Your Rights to the p	ardized atient,	I CMS pharmacy notice Med and advise the member, the	n cannot be filled as written, distribute dicare Prescription Drug Coverage and e member's appointed representative, through their prescription drug plan.

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging		Re	ecommended Action / Add	litional Detail
Opioid – Benzodiazepine Combination (Soft Reject)	CMS requires a soft reject for a combination of opioid and benzodiazepines.	88 – DUR Reject Error 569 – Provide Notice: Medicare Prescription Drug Coverage and Your Rights	Benzo+Opioid Hx Call MD Use DUR/PPS codes If > 50 MME: co- prescribe Naloxone for safety RxHelp 8007979791	benzodiazepine cla dispensed, triggerin Members are exempreceiving palliative anemia. Recommended Ac If the pharmacy has	im is sung a soft from care, are sconfir ative C	ubmitted, or for a benzodiaze ft reject. this restriction if they are in re treating cancer-related pa med the member should be are or being treated for cancer	bing claim for an opioid when a sepine claim when an opioid claim is Long-Term Care (LTC) or Hospice, ain, or are diagnosed with sickle cell exempt, due to the member being in cer-related pain, resubmit the claim
				Reason for Service Code	Pro	fessional Service Code	Result of Service Code
				DD Drug-Drug Interaction	MR N R0 P	Prescriber Consulted Medication Review harmacist Consulted Othr	4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice 4D Filled, Cancer Treatment 4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice
							if the prescriber confirms that the claim with the following DUR/PPS
				Reason for Serviced	vice	Professional Service Code	Result of Service Code
				DD Drug-Drug Interaction		M0 Prescriber Consulted	1G Filled, Prescriber Approvl
				a copy of the stand <u>Your Rights</u> to the p	ardized atient,	I CMS pharmacy notice Med and advise the member, the	n cannot be filled as written, distribute licare Prescription Drug Coverage and e member's appointed representative, through their prescription drug plan.

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging		R	ecommended Action / Add	ditional Detail	
Opioid – Prenatal Vitamin Combin ation (Soft Reject)	As part of the OptumRx Opioid Strategy, we recommend that plans place a soft reject for a combination of opioid and prenatal vitamins, to minimize risk to the mother and unborn child.	tegy, we that plans reject for a nof opioid all vitamins, to k to the unborn child. 569 - Provide Notice: Medicare Prescription Drug Coverage and Your Rights Use DUR/P codes RxHelp	569 – Provide Notice: Medicare Prescription Drug Coverage and Your Rights Call MD Use DUR/PPS codes RxHelp 8007979791	Clients have. OptumRx will look I prenatal vitamin cla dispensed, triggerin Members are exem receiving palliative anemia. Recommended Ac If the pharmacy has	pack in im is so a so pt from care, and tion at ive C	claim history to an overlappubmitted, or for a prenatal vift reject. this restriction if they are in re treating cancer related parameters that member should be are or being treated for cancer	ent the soft reject, the majority of our bing claim for an opioid when a tamin claim when an opioid claim is Long-Term Care (LTC) or Hospice, ain, or are diagnosed with sickle cell exempt, due to the member being in cer-related pain, resubmit the claim	
				Reason for Service Code	Pro	fessional Service Code	Result of Service Code	
				DD Drug-Drug Interaction Consult the prescri	MR N R0 P		4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice 4D Filled, Cancer Treatment 4B Filled, Palliative Care 4C Filled, Hospice 4D Filled, Cancer Treatment 4K Pscbr Expt – Cancer/PalCare 4L Pscbr Expt – Hospice if the prescriber confirms that the claim with the following DUR/PPS	
			Reason for Ser Code	vice	Professional Service Code	Result of Service Code		
					DD Drug-Drug Interaction		M0 Prescriber Consulted	1G Filled, Prescriber Approvl
			a copy of the stand Your Rights to the p	ardized atient,	d CMS pharmacy notice Med and advise the member, the	on cannot be filled as written, distribute dicare Prescription Drug Coverage and e member's appointed representative, through their prescription drug plan.		

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging		Recommended Action / Ad	ditional Detail
Opioid-APAP Exceeding 4,000mg APAP (Soft Reject)	The edit assesses the total acetaminophen daily dose based on FDA approved maximum dosing information. The edit identifies single incoming claims of concern, as well as overlapping claims with the member's history based on specific ingredient. The total daily dose across identified claims is then calculated. The edit will be triggered if total daily dose exceeds the FDA-defined maximum daily dose.	88 – DUR Reject Error 569 – Provide Notice: Medicare Prescription Drug Coverage and Your Rights	Opioid+APAP has APAP>4g Check dose To O/R submit DUR/PPS codes RxHelp 8007979791	Recommended Ad Pharmacies should The pharmacist will the Reason for Ser followed: Review the parapproved max Consult with the exceeding the Based on your of determined a appropriate Recommended appropriate Recommended appropriate Recommended appropriate Recommended Reason Code Reason Code Select the app	d use their professional judgment to II need to identify and enter the approvice, Professional and Result code attent profile to identify why the paticimum dose. The prescriber and/or the member as a FDA approved maximum dose is reclinical judgment, determine if the appropriate, override the rejection leason for Service, Professional, and or Service code below should autobelow of HD (High Dose Alert).	o review and override the rejection. propriate DUR/PPS Codes, including es. The following steps should be ent is filling greater than the FDA s needed to confirm the claim medically necessary. edrug should be dispensed. by identifying and entering the id Result code for each componentpopulate. If, not then use the
				Reason for Service Code HD High Dose Alert	Professional Service Code M0 Prescriber Consulted	Result of Service Code 1G Filled, Prescriber Approvl 1B Filled, Prescription As Is 1C Filled, Different Dose 1D Filled, Different Directns 1F Filled, Different Quantity 2A Prescription Not Filled 3C Discontinued Drug 3D Regimen Changed 3E Therapy Changed
					P0 Patient Consulted R0 Pharmacist Consulted Othr	1A Filled As Is, Falso Posity 3K Instructions Understood 1G Filled, Prescriber Approvl 1B Filled, Prescription As Is 1C Filled, Different Dose 1D Filled, Different Directns 1F Filled, Different Quantity 2A Prescription Not Filled 3C Discontinued Drug 3D Regimen Changed 3E Therapy Changed
				a copy of the stand Your Rights to the	dardized CMS pharmacy notice Me patient, and advise the member, th	on cannot be filled as written, distribute dicare Prescription Drug Coverage and e member's appointed representative, a through their prescription drug plan.

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging	Recommended Action / Additional Detail
Opioid Day Supply Limit	OptumRx® Medicare Part D members will be limited to a 30- day supply of opioid medication per prescription.	76 - Plan Limitations Exceeded 19 - M/I Days Supply	Opioid Maximum Days Supply of 30	Additional Detail If a Medicare Part D member was previously prescribed more than a 30-day supply of his or her opioid medication, and the member wishes to continue the medication through the OptumRx Medicare Part D benefit after January 1, 2019, then the prescriber may write a new prescription for up to a 30-day supply. Recommended Action Contact the prescriber for a new prescription written for a 30-day supply or less. Resubmit the prescription claim for a 30-day supply.
Opioid Refill Utilization Threshold	OptumRx is implementing a refill threshold for all opioid products of 90%. Refill threshold will be 80% at Home Delivery Pharmacy	79 - Refill Too soon, OR 88 - DUR Reject Error	Refill payable on or after [date of next allowed fill]	Notify member of the change in prescription day supply. Additional Detail If an opioid medication claim is submitted for either a refill or new prescription fill before the previous fill has reached 90% usage, the claim will reject. Recommended Action Resubmit the claim on the date of next allowed fill as defined in the returned message. Consult the prescriber to confirm attestation that the member must receive their prescription before the refill payable date and document the results. If the prescriber approves an early refill, call the pharmacy help desk for an override.
Controlled Substance Prescriber License and Scope of Practice Validation	OptumRx has a prescriber DEA license and scope of practice check at the Point of Sale (POS) for all Schedule II-V controlled medication claims to prevent payment of scheduled medication claims from unauthorized prescribers.	Reject 43: Plan's Prescriber database indicates the associated DEA to the submitted Prescriber ID is inactive. Reject 44: Plan's Prescriber database indicates the associated DEA to the submitted Prescriber ID is not found. Reject 46: Plan's Prescriber database indicates the associated DEA to the submitted Prescriber ID does not allow this drug DEA class.	Reject 43 POS Message: "Plan's Prescriber database indicates the associated DEA to submitted Prescriber ID is inactive. Prescriber is not authorized for drug's DEA class." Reject 44 POS Message: "Plan's Prescriber database indicates the associated DEA to submitted Prescriber ID is not found. Prescriber is not	Additional Detail The license and scope of practice check will validate submission of a valid, non-expired DEA prescriber license and then match the submitted prescriber's full two alphabetic letters and seven-digit numeric license number string to the submitted controlled drug GPI. Successful validation of these two steps will allow the claim to proceed to adjudication. However, failure of the check will result in a reject at the POS. Recommended Action If the pharmacy encounters any of the above noted rejects on a prescription claim, the pharmacy must follow the steps below to continue processing the claim for a paid response: 1. Obtain verification of the DEA license associated with the prescriber of the prescription and document on the original prescription hard copy. 2. Select one of the following numeric Submission Clarification Codes (SCCs) based upon the validation obtained in Step 1. Please note that only the codes listed below can be used to apply the DEA check verification override. a. Use code 43 if Prescriber's DEA is active with DEA Authorized Prescriptive Right. b. Use code 45 if Prescriber's DEA is a valid Hospital DEA with Suffix and has prescriptive authority for this drug DEA schedule. C. Use code 46 if Prescriber's DEA has prescriptive authority for this drug DEA schedule. 3. Enter the numeric SCC to process the claim; entry of the SCC in your pharmacy software entry field should now allow the claim to bypass the DEA check and send back a paid claim message if no other conflicting edits are found. In situations where the SCC still results in a rejected claim due to an invalid DEA number

Controlled	Based on DEA	Reject 17 – M/I Refill	authorized for drug's DEA class." Reject 46 POS Message: "Plan's Prescriber database indicates the associated DEA to submitted Prescriber ID does not allow this drug DEA class. Prescriber is not authorized for drug's DEA class."	The Pharmacy Hel prescriber's DEA li This process shou license verified an	armacy Help Desk must be contacted for assistance. Ip Desk can also assist in initiating a request for OptumRx to research the icense in question and perform a data validation and update. Ild be followed for those Prescribers who would like their individual DEA d updated in our records. Please allow for a 7 day turn-around time for prescriber information to be updated in the claim adjudication system.
Substance Refill Limits and Time Limits	regulations, some controlled substance schedules include refill limitations and time limits for filling those refills. Within RxClaim, OptumRx has DEA Edits known as Reject 17 (Refill Limit), and Reject 81 (Time Limit).	Reject 17 – M/I Reilli Number Reject 81 – Claim Too Old	I N/A	If partial fills are di from the Pharmacy If the pharmacy Additional Detail The federal and structure Schedules II – V (000 Regulatory Affairs) These limitations of which appear as resulting the pear as resulting to the pear and the pear an	spensed for terminally ill patients, the pharmacy may request an override y Help Desk. cy receives a reject 17 for a non-LTC claim, then a new prescription will be cy receives a reject 81 for a claim, then a new prescription will be required. atte specific refill limit and time limit requirements for controlled substance CII – CV) are researched and routinely monitored by the OptumRx Department, which includes internal OptumRx legal review. do not apply to long-term care (LTC) claims due to allowable partial fills, efills.

		functionality has been added to the RxClaim DEA Edit to ensure compliance with these requirements on both the federal and the State levels.
--	--	---

Drug Management Programs (DMP)

Medicare Part D plans may have a DMP that limits access to opioids and benzodiazepines for patients who are considered by the plan to be at risk for prescription drug abuse. The goal of a DMP is better care coordination for safer use. Patients are identified for the program by opioid use involving multiple doctors and pharmacies as well as a history of opioid overdose, and through case management conducted by the plan with the patients' prescribers.

Coverage limitations under a DMP can include:

- Requiring the patient to obtain these medications from a specified prescriber and/or pharmacy, or
- Implementing an individualized POS edit that limits the amount of these medications that will be covered for the patient.

Before a limitation is implemented, the plan must give written notice to the patient, and an opportunity to tell the plan which prescribers or pharmacies they prefer to use or provide additional information if they disagree with the plan's decision.

If the plan decides to limit coverage under a DMP, the patient and their prescriber have the right to appeal the plan's decision. Pharmacies are not expected to distribute the standardized CMS pharmacy notice *Medicare Prescription Drug Coverage and Your Rights* to the patient in response to a rejected claim related to a limitation under a DMP. The patient or prescriber should contact the plan for additional information on how to appeal.

Opioid Edit Name	Description	Standard Reject Code / Description	Standard Messaging	Recommended Action / Additional Detail
Prescriber Lock-in	Per the 2019 Final Rule and CARA guidance, sponsors are now able to implement prescriber lock-in edits as part of the Drug Management Program to help members more safely manage use their opioids and frequently abused drugs. OptumRx will implement a Prescriber Lock-in edit only with the consent and agreement of the designated prescriber for only opioid and/or benzodiazepine class drugs. This edit will prevent payment of the claim unless it is being prescribed by the designated prescriber of the Lock-in edit. The edit does not apply to drugs that are outside of the opioid and/or benzodiazepine classes, such as acute use medications, antibiotics, and maintenance medications.	828: Plan/Ben eficiary Case Management Restriction In Place. 979: Recipient Locked into Specific Prescriber(s)*	Drug Mgmt Prgrm Lockin Fax 877-239- 4565** **OptumRx standard fax for Appeals; clients who handle their own appeals will have the appropriate fax line display in the message for their respective members.	 Recommended Actions Advise member that prescriber of the claim is not authorized due to case management restriction. Direct member to contact their prescriber or authorized agent to initiate an appeal thru the number indicated in the reject message. Additional Details When a Drug Management Program restrictive edit is decided upon by OptumRx, we are required to send the member a series of written notifications to inform them of our decision and intent to implement the edit. The first letter called the Initial Member Notice is sent thirty days before the start date of the edit and also provides the member an opportunity to provide a response back. The second notice is called the Second Member Notice and is sent on the same day as the edit effective date. Therefore, members with DMP edits in place are provided due notice and opportunities to respond before there is any potential for disruption at point-of-sale.
Prescriber and Pharmacy Lock-in Edit	Per the 2019 Final Rule and CARA guidance, sponsors are now able to implement prescriber and pharmacy lock-in edits as part of the Drug Management Program to help members more safely manage use their opioids and frequently abused drugs. OptumRx will implement a Prescriber Lock-in edit only with the consent and agreement of the designated prescriber for	828: Plan/Ben eficiary Case Management Restriction In Place. 979: Recipient Locked into Specific Prescriber(s)* 980: Recipient Locked into Specific Pharmacy(s)*	Drug Mgmt Prgrm Lockin Fax 877-239- 4565** **OptumRx standard fax for Appeals; clients who handle their own appeals will have the appropriate fax line display in	 Recommended Actions Advise member that prescriber/dispensing pharmacy of the claim is not authorized due to case management restriction. Direct member to contact their prescriber or authorized agent to initiate an appeal thru the number indicated in the reject message.

Drug Level Edit PS1 Block All Opioids	only opioid and/or benzodiazepine class drugs; a Pharmacy Lock-in may also be implemented with the consent and agreement of the member's prescriber(s) or as an administrative edit decision. This edit will prevent payment of the claim unless it is being prescribed by the designated prescriber of the Lock-in edit AND filled at the designated pharmacy of the Lock-in edit. The edit does not apply to drugs that are outside of the opioid and/or benzodiazepine classes, such as acute use medications, antibiotics, and maintenance medications. In a Drug Level Edit PS1 Block All Opioids edit, OptumRx will implement a restrictive edit for a member that blocks payment of all opioids. This edit is implemented when the member's prescriber(s) do not attest that any opioid therapy is justified and medically necessary or that the member does not have any exemptions. The edit does not apply to opioid class medications indicated for medication assisted therapy (MAT, i.e. Suboxone).	828: Plan/Ben eficiary Case Management Restriction In Place.	Drug Mgmt Prespective members Drug Mgmt Prgrm Lockin Fax 877-239- 4565** Maximum Daily Dose of 0.0001 **OptumRx standard fax for Appeals; clients who handle their own appeals will have the appropriate fax line display in the message for their respective	Recommended Actions 1. Advise member that the claim is not covered because of a case management restrictive edit for all of their opioids 2. This is a hard edit that cannot be overridden at point of sale. 3. Direct member to contact their prescriber or authorized agent to initiate an appeal thru the number indicated in the reject message. Additional Details When a Drug Management Program restrictive edit is decided upon by OptumRx, we are required to send the member a series of written notifications to inform them of our decision and intent to implement the edit. The first letter called the Initial Member Notice is sent thirty days before the start date of the edit and also provides the member an opportunity to provide a response back. The second notice is called the Second Member Notice and is sent on the same day as the edit effective date. Therefore, members with DMP edits in place are provided due notice and opportunities to respond before there is any potential for disruption at point of sale.
Drug Level Edit PS2 Cover	In a Drug Level Edit PS2 Cover Only Approved	828: Plan/Ben eficiary Case	members Drug Mgmt Prgrm Lockin	Recommended Actions 1. Advise member that the claim is not covered because of a case management restrictive
Only Approved Opioids	Opioids, OptumRx will implement a restrictive	Management Restriction In Place.	Fax 877-239- 4565**	edit that applies to all of their opioids unless approved. 2. This is a hard edit that cannot be overridden at point of sale.

edit for a member that will block payment of all opioids except for what has been approved as justified and medically necessary for the member by the prescriber(s). This may include specific maximum daily doses (MDD) OR morphine milligram equivalent (MME) maximum daily doses.

Furthermore, the edit may allow only a single or multiple opioids for the member to continue receiving while blocking payment of all others. The edit does not apply to opioid class medications indicated for medication assisted therapy (MAT, i.e. Suboxone).

Maximum Daily Dose of #### (if MDD of approved opioid exceeded)

Maximum Daily Dose of 0.0001 (if not approved opioid)

MME ###.## exceeded; Ttl MME ###.## mg (if MME of approved opioid exceeded)

**OptumRx standard fax for Appeals; clients who handle their own appeals will have the appropriate fax line display in the message for their respective members 3. Direct member to contact their prescriber or authorized agent to initiate an appeal thru the number indicated in the reject message.

Additional Details

When a Drug Management Program restrictive edit is decided upon by OptumRx, we are required to send the member a series of written notifications to inform them of our decision and intent to implement the edit.

The first letter called the Initial Member Notice is sent thirty days before the start date of the edit and also provides the member an opportunity to provide a response back. The second notice is called the Second Member Notice and is sent on the same day as the edit effective date.

Therefore, members with DMP edits in place are provided due notice and opportunities to respond before there is any potential for disruption at point of sale.